Dana HorÃ¡kovÃ¡

List of Publications by Year
in descending order

146 papers	6,589 citations	71102 41 h-index	74163 75 g-index
150 all docs	150 docs citations	150 times ranked	5919 citing authors

#	Article	IF	Citations
1	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. European Journal of Neurology, 2022, 29, 1082-1090.	3.3	11
2	The clinical and paraclinical correlates of employment status in multiple sclerosis. Neurological Sciences, 2022, 43, 1911-1920.	1.9	4
3	Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic. Multiple Sclerosis and Related Disorders, 2022, 59, 103391.	2.0	7
4	Pregnancyâ€induced brain magnetic resonance imaging changes in women with multiple sclerosis. European Journal of Neurology, 2022, 29, 1446-1456.	3.3	7
5	Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. Frontiers in Immunology, 2022, 13, 818325.	4.8	5
6	Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation, 2022, 42, 355-364.	2.2	8
7	Time course of lesion-induced atrophy in multiple sclerosis. Journal of Neurology, 2022, 269, 4478-4487.	3.6	3
8	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	3.0	2
9	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	3.3	3
10	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. Neurology, 2022, 98, .	1.1	12
11	Periventricular gradient of T1 tissue alterations in multiple sclerosis. NeuroImage: Clinical, 2022, 34, 103009.	2.7	9
12	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
13	098â€... Treatment escalation in secondary progressive MS identified clinically and algorithmically in relapsing remitting (RR)MS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A131.2-A131.	1.9	0
14	To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection. Multiple Sclerosis and Related Disorders, 2022, 65, 104014.	2.0	17
15	Neurofilament levels are associated with bloodâ€“brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 220-231.	3.0	55
16	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	3.0	11
17	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 52-60.	3.0	41
18	Interpretation of Brain Volume Increase in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 401-407.	2.0	6

#	Article	IF	Citations
19	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	3.0	3
20	Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. Diagnostics, 2021, 11, 464.	2.6	9
21	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
22	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.1	41
23	Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. Multiple Sclerosis and Related Disorders, 2021, 50, 102778.	2.0	7
24	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, e869-e880.	1.1	15
25	004â€...Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
26	The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
27	Age-related magnetic susceptibility changes in deep grey matter and cerebral cortex of normal young and middle-aged adults depicted by whole brain analysis. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3906-3919.	2.0	16
28	Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. Multiple Sclerosis and Related Disorders, 2021, 54, 103104.	2.0	23
29	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	5.9	8
30	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Journal of the Neurological Sciences, 2021, 430, 118067.	0.6	9
31	Validating atlas-based lesion disconnectomics in multiple sclerosis: A retrospective multi-centric study. NeuroImage: Clinical, 2021, 32, 102817.	2.7	4
32	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.1	54
33	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2001-2013.	3.0	9
34	Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis. Diagnostics, 2021, 11, 2230.	2.6	2
35	The influence on long-term progression of multiple sclerosis - brighter days ahead?. Neurologie Pro Praxi, 2021, 22, 40-44.	0.1	0
36	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	3.0	52

#	Article	IF	Citations
37	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
38	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. Multiple Sclerosis and Related Disorders, 2020, 46, 102534.	2.0	14
39	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. JAMA Neurology, 2020, 77, 1496.	9.0	21
40	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. Journal of Clinical Lipidology, 2020, 14, 675-684.e2.	1.5	8
41	Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study. Multiple Sclerosis and Related Disorders, 2020, 46, 102543.	2.0	13
42	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. JAMA Neurology, 2020, 77, 1398.	9.0	21
43	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24
44	Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642097522.	3.5	5
45	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	7.6	32
46	Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis. BioMed Research International, 2020, 2020, 1-6.	1.9	13
47	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	10.2	219
48	Characterizing vocal tremor in progressive neurological diseases via automated acoustic analyses. Clinical Neurophysiology, 2020, 131, 1155-1165.	1.5	18
49	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	24
50	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732097213.	1.0	9
51	Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 820.	2.4	16
52	Lifespan normative data on rates of brain volume changes. Neurobiology of Aging, 2019, 81, 30-37.	3.1	40
53	Brain volumetric correlates of dysarthria in multiple sclerosis. Brain and Language, 2019, 194, 58-64.	1.6	16
54	Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study. Journal of Clinical Neuroscience, 2019, 65, 28-33.	1.5	16

#	Article	IF	Citations
55	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	1.9	71
56	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	2.0	35
57	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336
58	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	3.0	55
59	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 541-553.	3.0	32
60	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients. Journal of the Neurological Sciences, 2018, 388, 87-93.	0.6	7
61	Establishing pathological cut-offs for lateral ventricular volume expansion rates. NeuroImage: Clinical, 2018, 18, 494-501.	2.7	26
62	Reply to: Comment on Y.D. Fragoso et al.: â€œLymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodâ€•[Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	2.0	0
63	Management of multiple sclerosis patients in central European countries: current needs and potential solutions. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641875918.	3.5	17
64	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders, 2018, 19, 105-108.	2.0	22
65	The Role of Highâ€Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 328-337.	2.0	4
66	Cognitive clinicoâ€radiological paradox in early stages of multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 81-91.	3.7	26
67	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	3.0	37
68	Cladribine versus fingolimod, natalizumab and interferon Î² for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1617-1626.	3.0	36
69	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. NeuroImage: Clinical, 2018, 17, 444-451.	2.7	58
70	Characteristics of motor speech phenotypes in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 19, 62-69.	2.0	58
71	Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. Multiple Sclerosis Journal, 2017, 23, 242-252.	3.0	39
72	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 51-61.	3.0	39

#	Article	IF	Citations
73	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	3.0	30
74	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	1.9	49
75	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134
76	Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis. American Journal of Neuroradiology, 2017, 38, 1079-1086.	2.4	29
77	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Longâ€Term Comparative Study. Journal of Neuroimaging, 2017, 27, 620-629.	2.0	20
78	MxA <scp>mRNA</scp> decrease preceding <scp>NA</scp>b detection in <scp>IFN</scp>Î²â€treated <scp>MS</scp> patients. Brain and Behavior, 2017, 7, e00644.	2.2	1
79	Serum lipid profile changes predict neurodegeneration in interferon-Î²1a-treated multiple sclerosis patients. Journal of Lipid Research, 2017, 58, 403-411.	4.2	43
80	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.1	38
81	Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology, 2017, 313, 89-91.	2.3	8
82	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. NeuroImage: Clinical, 2017, 15, 769-779.	2.7	48
83	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis Journal, 2017, 23, 1346-1357.	3.0	18
84	Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. European Journal of Neurology, 2017, 24, 292-301.	3.3	38
85	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	7.6	94
86	Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients. BMC Neurology, 2017, 17, 145.	1.8	10
87	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1423-1437.	2.0	25
88	Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNÎ². PLoS ONE, 2017, 12, e0169957.	2.5	1
89	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	1.9	90
90	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	7.6	281

#	Article	IF	Citations
91	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. European Journal of Neurology, 2016, 23, 729-736.	3.3	21
92	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	1.9	63
93	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	1.6	33
94	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Review of Neurotherapeutics, 2016, 16, 777-793.	2.8	126
95	Reliable measurements of brain atrophy in individual patients with multiple sclerosis. Brain and Behavior, 2016, 6, e00518.	2.2	58
96	Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.4	13
97	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335.	8.1	24
98	Predictors of longâ€term disability accrual in relapseâ€onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	5.3	158
99	Alemtuzumab long-term immunologic effect. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e194.	6.0	65
100	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Multiple Sclerosis Journal, 2016, 22, 1709-1718.	3.0	69
101	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Multiple Sclerosis Journal, 2016, 22, 770-781.	3.0	37
102	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	3.0	34
103	Neuromyelitis optica (Devic's disease) - a rare demyelinating disease. MedicÃna Pro Praxi, 2016, 13, 43-46.	0.0	0
104	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	5.3	143
105	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
106	Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Therapeutic Advances in Neurological Disorders, 2015, 8, 31-45.	3.5	134
107	Early magnetic resonance imaging predictors of clinical progression after 48Âmonths in clinically isolated syndrome patients treated with intramuscular interferon Î²â€1a. European Journal of Neurology, 2015, 22, 1113-1123.	3.3	25
108	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	9.0	100

#	Article	IF	Citations
109	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. Journal of Lipid Research, 2015, 56, 2010-2018.	4.2	45
110	Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. American Journal of Neuroradiology, 2015, 36, 1457-1464.	2.4	13
111	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	7.6	162
112	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	3.0	36
113	Neuromyelitis Optica Spectrum Disorders â€“â€Š Retrospective Analysis of Clinical and Paraclinical Findings. Ceska A Slovenska Neurologie A Neurochirurgie, 2015, 78/111, 72-77.	0.1	2
114	MRI correlates of disability progression in patients with CIS over 48Âmonths. NeuroImage: Clinical, 2014, 6, 312-319.	2.7	39
115	Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. Journal of the Neurological Sciences, 2014, 347, 229-234.	0.6	8
116	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. Journal of Neuroimmunology, 2014, 273, 58-64.	2.3	21
117	A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility. Genes and Immunity, 2014, 15, 126-132.	4.1	26
118	Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology, 2014, 274, 185-191.	2.3	54
119	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 424-433.	2.5	14
120	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 859-864.	1.9	35
121	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. Journal of Neurology, 2014, 261, 1735-1744.	3.6	45
122	Development of gray matter atrophy in relapsingâ€“remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. Clinical Neurology and Neurosurgery, 2013, 115, S42-S48.	1.4	12
123	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. Journal of Neuroimmunology, 2013, 263, 121-127.	2.3	14
124	Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. Genes and Immunity, 2013, 14, 244-248.	4.1	18
125	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. Radiology, 2013, 268, 831-841.	7.3	145
126	Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years. American Journal of Neuroradiology, 2013, 34, 1931-1939.	2.4	90

#	Article	IF	Citations
127	Lipid profiles are associated with lesion formation over 24â€…months in interferon-Î² treated patients following the first demyelinating event. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1186-1191.	1.9	114
128	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. Multiple Sclerosis International, 2013, 2013, 1-8.	0.8	9
129	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. PLoS ONE, 2013, 8, e53996.	2.5	68
130	Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1573-1578.	2.4	133
131	Restless legs syndrome in Czech patients with multiple sclerosis: An epidemiological and genetic study. Sleep Medicine, 2012, 13, 848-851.	1.6	38
132	Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clinical Neurology and Neurosurgery, 2012, 114, 940-946.	1.4	18
133	Corpus Callosum Atrophy â€“ A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study. European Neurology, 2012, 68, 23-27.	1.4	32
134	Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study. PLoS ONE, 2012, 7, e50101.	2.5	73
135	Early predictors of non-response to interferon in multiple sclerosis. Acta Neurologica Scandinavica, 2012, 126, 390-397.	2.1	22
136	Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurology, 2012, 12, 10.	1.8	55
137	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. Journal of Neuroimmunology, 2011, 236, 76-80.	2.3	12
138	Multiple Sclerosis and the Accumulation of Iron in the Basal Ganglia: Quantitative Assessment of Brain Iron Using MRI T₂ Relaxometry. European Neurology, 2010, 63, 136-143.	1.4	50
139	Patientsâ€™ Stratification and Correlation of Brain Magnetic Resonance Imaging Parameters with Disability Progression in Multiple Sclerosis. European Neurology, 2009, 61, 278-284.	1.4	10
140	Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 965-976.	3.0	77
141	Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurology, The, 2009, 8, 1111-1119.	10.2	233
142	Gray matter atrophy and disability progression in patients with early relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 112-119.	0.6	84
143	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, The, 2008, 372, 1463-1472.	13.7	457
144	Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 407-414.	1.9	73

#	Article	IF	Citations
145	Detection of Cortical Lesions is Dependent on Choice of Slice Thickness in Patients with Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 475-489.	2.0	25
146	Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clinica Chimica Acta, 2004, 348, 147-154.	1.1	22